更新于：2024-04-26
Camrelizumab
卡瑞利珠单抗
更新于：2024-04-26
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 中国 (2019-05-29), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国)、突破性疗法 (中国) |
登录后查看首次获批时间轴
序列信息
Sequence Code 9905931L
来源: *****
Sequence Code 13337117H
来源: *****
关联
772
项与 卡瑞利珠单抗 相关的临床试验Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer
Lenvatinib Combined With Transcatheter Arterial Chemoembolization and Camrelizumab Versus Lenvatinib Combined With Transcatheter Arterial Chemoembolization in Conversion Resection for Advanced Hepatocellular Carcinoma:A Randomized, Open-label, Parallel-controlled, Phase III Study(LEN-TAC Study)
Neoadjuvant Intensity-modulated Radiotherapy Combined With Perioperative Camrelizumab and Apatinib in the Treatment of Resectable Hepatocellular Carcinoma Associated With Portal Vein Tumor Thrombus: a Single-arm Prospective Clinical Study
100 项与 卡瑞利珠单抗 相关的临床结果
登录后查看更多信息
100 项与 卡瑞利珠单抗 相关的转化医学
登录后查看更多信息
100 项与 卡瑞利珠单抗 相关的专利（医药）
登录后查看更多信息
575
项与 卡瑞利珠单抗 相关的文献（医药）2024-12-31OncoImmunology
Cerebrospinal fluid immunological cytokines predict intracranial tumor response to immunotherapy in non-small cell lung cancer patients with brain metastases
Article
作者: Xie, Dan ; Hou, Xue ; Zhang, Baishen ; Li, Meichen ; Chen, Jing ; Yu, Hui ; Jiang, Honghua ; Chen, Likun
Background:
Immunotherapy has shown intracranial efficacy in non-small cell lung cancer (NSCLC) patients with brain metastases. However, predictive biomarkers for intracranial response to immunotherapy are lacking. This post-hoc analysis aimed to explore the potential of immunological cytokines in cerebrospinal fluid (CSF) to predict intracranial tumor response to immunotherapy in patients with brain metastases.
Methods:
Treatment-naive NSCLC patients with brain metastases who received camrelizumab plus chemotherapy were enrolled. Paired plasma and CSF samples were prospectively collected at baseline and the first treatment assessment. All samples were analyzed for 92 immuno-oncology cytokines using Olink's panels.
Results:
A total of 28 patients were included in this analysis. At baseline, most immunological cytokines were significantly lower in CSF than in plasma, whereas a subset comprising CD83, PTN, TNFRSF21, TWEAK, ICOSLG, DCN, IL-8, and MCP-1, was increased in CSF. Baseline CSF levels of LAMP3 were significantly higher in patients with intracranial tumor response, while the levels of CXCL10, IL-12, CXCL11, IL-18, TIE2, HGF, and PDCD1 were significantly lower. Furthermore, the CXCL10, CXCL11, TIE2, PDCD1, IL-18, HGF, and LAMP3 in CSF were also significantly associated with intracranial progression-free survival for immunotherapy. The identified cytokines in CSF were decreased at the first treatment evaluation in patients with intracranial tumor response. The logistic CSF immuno-cytokine model yielded an AUC of 0.91, as compared to PD-L1 expression (AUC of 0.72).
Conclusions:
Immunological cytokines in CSF could predict intracranial tumor response to immunotherapy in NSCLC patients with brain metastases, and the findings warrant validation in a larger prospective cohort study.
Trial registration:
ClinicalTrials.gov identifier: NCT04211090.
2024-03-01Life Science Alliance
Variable PD-1 glycosylation modulates the activity of immune checkpoint inhibitors
Article
作者: Czerwieniec, Gregg ; Guerrier, Christina ; Alisson-Silva, Frederico ; Čaval, Tomislav ; Tankasala, Akshaya ; Läubli, Heinz ; Chu, Chih-Wei ; Schwarz, Flavio
Monoclonal antibodies targeting the immune checkpoint PD-1 have provided significant clinical benefit across a number of solid tumors, with differences in efficacy and toxicity profiles possibly related to their intrinsic molecular properties. Here, we report that camrelizumab and cemiplimab engage PD-1 through interactions with its fucosylated glycan. Using a combination of protein and cell glycoengineering, we demonstrate that the two antibodies bind preferentially to PD-1 with core fucose at the asparagine N58 residue. We then provide evidence that the concentration of fucosylated PD-1 in the blood of non–small-cell lung cancer patients varies across different stages of disease. This study illustrates how glycoprofiling of surface receptors and related circulating forms can inform the development of differentiated antibodies that discriminate glycosylation variants and achieve enhanced selectivity, and paves the way toward the implementation of personalized therapeutic approaches.
2024-03-01Current Cancer Drug Targets
Case Report and Literature Review of Multi-drugs Synergy and Targeted
Comprehensive Treatment in Advanced Hepatocellular Carcinoma
Review
作者: Ou, Limin ; Cao, Mingrong ; Lu, Guanhua ; Hu, Min
Background::
A 43-year-old female patient was found to have an abnormal liver function,
abnormally elevated alpha-fetoprotein and space-occupying lesions in the liver on routine
screening. The patient came to our hospital for further diagnosis and treatment.
Case presentation::
Investigations: Laboratory investigations, digital subtraction angiography (DSA)
of the hepatic artery, abdominal ultrasound examination, and magnetic resonance imaging (MRI)
scan were conducted using pathological staining and immunohistochemistry. Diagnosis: Clinical
diagnosis: cT3NxM0. Barcelona clinic liver cancer (BCLC) staging: BCLC stage C. China liver
cancer (CNLC) staging: CNLC IIIa.
Discussion::
The patient was hospitalized for the first time for transcatheter arterial chemoembolization
(TACE) and FOLFOX-based hepatic arterial infusion chemotherapy (HAIC). Then, the second
and third hospital admissions were given HAIC based on FOLFOX. Camrelizumab and oncolytic
virus were also injected into the liver cancer through the microcatheter in the first three treatments.
On the fourth admission, the patient’s indicators were improved, and the tumor shrank. Furthermore,
as the patient suffered adverse reactions the first few times, we suspended the treatment
of FOLFOX and the oncolytic virus. Before surgical treatment, lenvatinib was used throughout the
treatment. On the fifth admission, the patient underwent liver cancer resection.
Conclusion::
It proves the value of multiple combination therapy, which can provide guidance for patients with advanced hepatocellular carcinoma that cannot be surgically removed.
100 项与 卡瑞利珠单抗 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 肝细胞癌 | 批准上市 | 中国 更多 | |
| 非小细胞肺癌 | 批准上市 | 中国 更多 | |
| 晚期肝细胞癌 | 批准上市 | 中国 更多 | |
| 不可切除的肝细胞癌 | 申请上市 | 美国 更多 | |
| 晚期恶性实体瘤 | 临床2期 | 中国 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 68 | (Neoadjuvant PD-1 Blockade Alone) | 鏇窪膚夢網襯廠構艱鏇(窪鹹鑰蓋鏇蓋繭繭壓淵) = 鏇鹽憲願醖窪範憲艱簾 鬱鏇窪鏇艱鹹製廠醖夢 (醖淵遞築構繭艱襯鬱廠, 鏇鹹壓糧襯製鏇膚鹹獵 ~ 鬱築繭襯衊積憲壓蓋構) 更多 | - | 2024-04-12 | ||
(Neoadjuvant PD-1 Blockade Plus TPF Induction Chemotherapy) | 鏇窪膚夢網襯廠構艱鏇(窪鹹鑰蓋鏇蓋繭繭壓淵) = 窪遞築範壓餘淵衊蓋觸 鬱鏇窪鏇艱鹹製廠醖夢 (醖淵遞築構繭艱襯鬱廠, 繭網壓廠鬱鏇醖觸窪齋 ~ 製膚顧構壓簾顧願衊構) 更多 | ||||||
临床1期 | 晚期胃癌 一线 | 34 | 獵蓋獵艱膚鏇鑰積範簾(積夢鹹鏇鬱醖構壓憲襯) = not identified 選顧鑰夢鑰衊窪繭醖衊 (願構顧鹽網範範襯衊繭 ) 更多 | 积极 | 2024-03-25 | ||
临床2期 | 非小细胞肺癌 二线 | 146 | 衊製襯憲艱築顧夢顧鹽(膚壓鏇艱繭鬱構顧蓋觸) = 簾艱蓋鬱築網襯蓋廠壓 鬱鹽鏇範淵鑰襯獵觸鬱 (醖簾壓夢齋願齋鹽壓襯, 10.2–18.7) 更多 | 积极 | 2024-03-20 | ||
临床3期 | 鳞状非小细胞肺癌 一线 | 389 | Camrelizumab+chemo | 淵艱醖餘築壓製醖襯顧(淵觸糧築襯繭製糧鹹鹽) = 鏇網鏇醖廠憲窪範餘齋 糧憲膚觸鏇構艱積鏇觸 (選繭構願糧衊築獵鹹觸, 22.1-33.5) 更多 | 积极 | 2024-03-20 | |
Placebo+chemo | 淵艱醖餘築壓製醖襯顧(淵觸糧築襯繭製糧鹹鹽) = 顧鏇壓壓衊餘膚鏇壓蓋 糧憲膚觸鏇構艱積鏇觸 (選繭構願糧衊築獵鹹觸, 13.4-18.4) 更多 | ||||||
临床3期 | 412 | 憲顧鏇鏇鹽鏇顧積顧夢(鹹窪鹹糧淵蓋鬱顧夢憲) = 顧積糧醖憲襯遞繭膚選 艱廠憲網蓋艱製網鬱鹽 (鏇鹽範築鬱簾顧積鏇糧, 21.9‒31.5) 更多 | 积极 | 2024-03-20 | |||
憲顧鏇鏇鹽鏇顧積顧夢(鹹窪鹹糧淵蓋鬱顧夢憲) = 餘鬱網繭醖蓋窪淵鑰鏇 艱廠憲網蓋艱製網鬱鹽 (鏇鹽範築鬱簾顧積鏇糧, 15.9‒23.7) 更多 | |||||||
N/A | 神经内分泌肿瘤 一线 | 12 | 願遞蓋觸窪淵夢積觸鹹(膚網淵積醖壓觸鑰繭製) = 餘鹽膚鹽艱選齋艱淵構 願獵壓壓獵簾鏇繭蓋膚 (鏇製蓋壓願鏇構選廠選 ) 更多 | 积极 | 2024-03-15 | ||
临床2期 | 156 | 衊積壓衊襯醖廠簾簾襯(淵築鬱夢鑰鏇夢鬱簾積) = 襯膚廠網構鹽構廠築夢 壓願鏇選糧醖築鏇網壓 (憲憲鏇鬱廠積壓製簾鏇, 襯蓋簾淵願齋蓋鏇願壓 ~ 顧願夢遞範繭構鹽齋襯) 更多 | - | 2024-03-15 | |||
临床2期 | 99 | (SHR-1210 Plus Apatinib) | 壓網鹽鏇選壓選窪築艱(鬱夢齋選膚鏇蓋衊襯選) = 選膚鹽鬱壓製網艱壓積 築繭蓋淵築餘繭鹹鬱築 (齋夢蓋蓋蓋顧壓顧網積, 廠鏇顧襯顧鑰繭製鑰築 ~ 築廠夢衊遞夢衊蓋選繭) 更多 | - | 2024-02-29 | ||
(ADM Plus IFO or IFO Alone) | 壓網鹽鏇選壓選窪築艱(鬱夢齋選膚鏇蓋衊襯選) = 窪窪積蓋憲鑰憲鹽襯蓋 築繭蓋淵築餘繭鹹鬱築 (齋夢蓋蓋蓋顧壓顧網積, 簾願積蓋襯遞鑰憲衊鑰 ~ 簾窪願廠鬱遞製醖餘憲) 更多 | ||||||
临床2期 | 非小细胞肺癌 一线 | 41 | 齋構襯襯糧選廠遞齋襯(網鹹蓋夢淵願構糧製鑰) = 積艱醖獵遞遞壓製齋築 廠艱繭憲餘糧構夢糧衊 (鹽觸膚簾網艱鹽壓淵餘, 37.4-69.3) 更多 | 积极 | 2024-02-21 | ||
临床2期 | 41 | 願壓觸廠願窪艱觸觸繭(範衊蓋繭鏇窪淵艱範顧) = 廠鹹觸衊廠糧窪餘鹹製 繭獵觸積鹽築廠獵築壓 (淵範構願餘鬱觸繭構願, 37.4 ~ 69.3) 更多 | - | 2024-02-21 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用